Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Candace Westgate

Obstetrics & Gynecology Indianapolis, IN Doctor of Osteopathy

NPI 1669607735 CMS profile 581466

7120 Clearvista Dr Ste 2000, Indianapolis, IN 46256

Open in the dashboard

General payments

$123,251

349 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Candace Westgate of Indianapolis, IN is reported in the CMS Open Payments database as having received $123,251 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,333 21
2024 General $17,628 61
2023 General $64,578 164
2022 General $28,590 48
2021 General $9,244 18
2020 General $280 12
2019 General $599 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Candace Westgate
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Candace Westgate were reported at $2,333. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Candace Westgate Obstetrics & Gynecology median Middle half National median
2019 $599 $172 $62–$391 $163
2020 $280 $94 $36–$222 $114
2021 $9,244 $136 $42–$369 $132
2022 $28,590 $160 $50–$433 $149
2023 $64,578 $169 $56–$423 $160
2024 $17,628 $152 $50–$371 $164
2025 $2,333 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Myriad Genetic Laboratories, Inc. $60,552 97 payments
  2. Myriad Women's Health, Inc. $56,461 131 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $1,982 16 payments
  4. Applied Medical Resources Corporation $1,098 3 payments
  5. Astellas Pharma US Inc $485 11 payments
  6. Tempus AI, Inc $350 3 payments
  7. AstraZeneca Pharmaceuticals LP $346 5 payments
  8. AMAG Pharmaceuticals, Inc. $240 17 payments
  9. TherapeuticsMD, Inc. $239 11 payments
  10. Organon LLC $209 10 payments
  11. Other $1,288 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $72,695 53 payments
  2. Consulting Fee $26,775 29 payments
  3. Travel and Lodging $11,745 92 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,950 6 payments
  5. Food and Beverage $4,652 149 payments
  6. Education $434 20 payments
Products named General payments · program years 2019–2025
  1. myRisk Oncology $79,470 184 payments
  2. myRisk Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis $32,514 35 payments
  3. BRACAnalysis $1,750 2 payments
  4. Lynkuet $1,617 2 payments
  5. GELPOINT V-PATH $1,098 3 payments
  6. BRAC CDx $1,050 1 payment
  7. GENESIGHT $1,050 1 payment
  8. myChoice CDx Tumor Dna Genetic Oncology Analysis $700 2 payments
  9. Veozah $363 9 payments
  10. MyChoice CDx Oncology $350 1 payment
  11. Other $3,130 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

526

Median for Obstetrics & Gynecology: 65

Drug cost

$53,791

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

40.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 225 $24,246
Estring Estradiol Brand 21 $11,075
Estradiol (Twice Weekly) Estradiol Brand 48 $6,439
Yuvafem Estradiol Brand 37 $5,850
Dotti Estradiol Brand 25 $2,640
Progesterone Progesterone, Micronized Brand 63 $1,911
Raloxifene Hcl Generic 18 $532
Valacyclovir Valacyclovir Hcl Brand 17 $453
Metronidazole Generic 13 $360
Alendronate Sodium Generic 22 $175

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$61,743

Of which drugs: $1,064

Medicare patients

271

Average age 72

Services billed

628

251 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 46%
Osteoporosis 30%
Cancer 24%
Depression 17%
Ischemic heart disease 14%
Diabetes 13%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 12 12 $982

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $248
$248 — —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $100
$100 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $26
  • Lilly USA, LLC $9
$35 — —
ZEPBOUND
  • Lilly USA, LLC $9
$9 — —
Mirena
  • Bayer HealthCare Pharmaceuticals Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record